By a GenomeWeb staff reporter



NEW YORK (GenomeWeb News) – Rosetta Genomics' first-half 2011 revenues fell 39 percent year over year, the Israeli microRNA-based molecular diagnostics company reported after the close of the market on Friday.

In a document filed with the US Securities and Exchange Commission, it said that revenues for the first six months of the year came in at $59,000, down from $97,000 a year ago.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In PNAS this week: rare variants linked to bleeding disorder, comparison of whole-exome and whole-genome sequencing, and more.

George Church tells The Sunday Times that his group has inserted some woolly mammoth genes into elephant cells.

A Scientific Reports editor resigns over a new policy at the journal allowing researchers to pay to fast track the peer review of their manuscripts, and poll.

The National Cancer Institute's Harold Varmus discusses the state of cancer research with the New York Times.